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ABSTRACT
Continuous subcutaneous insulin infusion with an insulin pump provides best practice for prevention of tertiary complications of
insulin-dependent diabetes. Purpose: The aim of the study was to identify self-care adjustment issues to pump technology via a
computer-based survey. Method: Internal reliability of the Adaptation to Insulin Pumps Survey was 0.765 (Cronbach’s alpha).
The validated survey was emailed to a convenience sample of 10,000 users. Logistic regression analysis was done on each
binary variable, testing for Group effect, while controlling for age and gender. Results: There were 959 responders. Seventeen
survey statements relating to barriers, intrusiveness, attitude, and adaptations had significance from p<0.0001 to p<0.05.
Conclusions: Ninety-four percent of calculated p values of statements were higher for woman than men. Odds ratio estimates
suggested that women may have higher risk for discontinuance of the biomedical device than men. Future research should
identify women at risk and clarify the roles of different healthcare practitioners in addressing the self-care adjustment issues of
women.
INTRODUCTION
The International Diabetes Federation reported that 371 million people worldwide had diabetes in 2012, surpassing prior
projections of 380 million by 2025, and demonstrating that the global diabetes epidemic is rapidly exceeding expectations.1 U.S.
figures have forecasted that one third of the population may have diabetes by 2050.2
Two landmark studies established intensive management as the goal standard for diabetes care for people with type 1 diabetes
mellitus (T1DM). The research demonstrated that tight control of blood glucose with either continuous subcutaneous insulin
infusion (CSII) or multiple daily injections (MDI) prevented or delayed the onset of long-term peripheral micro- and macrovascular complications, cardiovascular disease, nephropathy, and retinopathy. Additionally, tighter control was found to extend
life by as much as five years. Yet, tighter control of glucose resulted in substantially more hypoglycemic episodes for people with
T1DM. 3,4 In 2009, the U.S. dominated the world market at $394 million for CSII devices with tubes and at $58.9 million for
tubeless CSII devices. In addition, the U.S. market was forecasted to reach $843 million and the worldwide market that was $586
million was predicted to be $1,051 million by 2016.5
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CSII was found to be the superior treatment for reduction of the number of hyperglycemic episodes and for slowing down the
onset of hypoglycemic symptoms. 3,4 However, the longer the duration that people had T1DM, the more they were at greater risk
for losing their ability to detect the symptoms of life-threatening hypoglycemia. For some people with T1DM that experienced
elevated glucose in early morning hours (called the dawn phenomena), it was found that CSII devices offered an easier solution
to control the elevation than by an injection before dawn.6 CSII has also been considered the best strategy for providing
incremental infusions of insulin to maintain optimal glycemic control for people having T1DM.7 CSII provided a means for
achieving near-normoglycemia, leading to improved metabolic outcomes, prevention and reduction of tertiary complications,
improved quality of life, and sustained productivity of people with diabetes.8 CSII devices have been prescribed for some people
with type 2 diabetes mellitus9 (T2DM) and for women with gestational diabetes.10 The terms CSII device and pump were used
interchangeably throughout this paper.
Many meta-analyses have focused on the benefits and positive outcomes of CSII devices with children and adolescents, as
researchers have been most concerned about the risks and benefits with youth rather than adults.11 One meta-analysis
performed an evaluation of 44 Randomized Controlled Trial (RCT) studies. It was found that MDI in children and adolescents
with T1DM and T2 DM were as effective as CSII. They also showed that in adults with T1DM, the glycosylated hemoglobin A1c
assay (HbA1c), the gold standard for determination of overall glucose control, was significantly more reduced in subjects with
CSII than MDI.12 Lower HbA1c readings have been associated with the best glycemic control. 3
CSII devices are programmable external pumps that continuously deliver short-acting insulin from a reservoir by means of a
cannula that is inserted under the skin. Dosages with CSII devices can be fine-tuned to increments of 0.025, 0.05 or 0.01 of a
unit of insulin to achieve precision control depending on the insulin pump product, thus providing less glycemic excursion for
users. A continuous background of insulin (the basal rate) is delivered 24 hours/day. A single dose of insulin (called a bolus) is
calculated from carbohydrate intake that can be given before meals, giving more flexibility for timing of meals than with MDI.13
Individualized treatment plans can be programmed into the device with: numerous basal rates introduced at different times of the
day, calculated correction bolus doses based on individualized formulas that address high or low glucose readings, formulas for
calculating insulin based on carbohydrate food intake, and suspension of basal rates during exercise. People on multiple daily
doses may take as many as 1,460 injections or more per year, whereas pump sets are changed only every two to three days,
creating less pain and increased lifestyle flexibility.13
People with diabetes who want to switch from MDI to CSII must demonstrate to their physicians and third party payers that they
are capable of adapting to the technology before they are approved for the device. Third party payers have similar
comprehensive criteria that candidates must meet before CSII can be considered as an option for treatment such as: history of
diabetes education, taking three or more injections per day for six months, and checking blood glucose at least four times daily
for two or more months. In addition, candidates must have one of the following medical necessity: a history of recurrent
hypoglycemia, wide glycemic excursions, a glycosylated hemoglobin level > 7.0%, or a blood glucose > 200mg/dl before dawn.14
METHODS
Aim and Research Question
The aim of this pilot study was to inquire about issues of adjustment that may be experienced by users of CSII devices. The
research question was: Are there adjustment issues to CSII devices that differ between first time users and second time users?
Studying the differences between experienced and non-experienced users was deemed important because health care
practitioners may want to seek early referrals from physicians to provide help to identified users, who seem to be making a poor
adjustment, before they stop using the technology and forgo their opportunity to achieve their optimal health.
Setting, Timelines, and Support
The study was conducted at the researchers’ university. There was a one year period allocated for literature review, design and
testing of the survey, collection of data, statistical analysis, and thesis project completion, in order to provide faculty support to a
candidate for a Master’s degree in occupational therapy. Faculty included an occupational therapist, biomedical engineer and a
statistician.
Participants
Participants comprised of a small nationwide convenience sample of insulin pump users, 18 to 71+ years, who were either First
Time Users (FTUs) of tubeless a CSII device or Second Time Users (STUs) that switched from tube technology to tubeless
pump technology, and had insurance coverage and computer access. Participants were acquired from the Insulet Corporation’s
10,000+ e-mail distribution list. The Insulet Corporation manufactured the first tubeless type insulin pump, called the Omnipod.15
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The manufacturer’s sample provided our researchers access to users of a variety of CSII devices with tubes and without tubes.
Survey Development
Survey method was deemed to be adequate for gathering data about group adjustment to technology. Adaptation to Insulin
Pumps Survey was a 17-item instrument that was developed by the two occupational therapist members of the research team. A
university technology manager uploaded the survey online using PHP with Microsoft SQL as the database, and downloaded all
data for the researchers.
An initial survey with 52 statements was derived using a 5-point Likert rating scale. The statements were allocated to represent
one of four categories: barriers (defined as an obstacle that hinders or prevents action)16; intrusiveness (described as the
perceived interruptions to participation in valued activities, due to considerations imposed by diabetes) 17; attitude (termed, “the
relatively stable set of beliefs, feelings, and behavioral tendencies in relations to something or someone”18; and adaptation
(defined as “the internal process by which people respond to the demand for change”).19
Content validity and face validity of the 52 statement survey was confirmed by an expert panel comprised of three university
faculty with type1 diabetes, who used CSII devices, and 10 key informants from the Insulet Corporation, who were clinical
service managers that trained clients in use of their new Omnipod devices. Panel members separately rated the statements and
provided feedback regarding content brevity, clarity, realism, simplicity and readability. The researchers deleted one statement
targeting intimacy, at the request of panel members, reducing the questionnaire to 51 statements.
To determine reliability, the questionnaire was given online to the first 15 men and 15 women volunteers that provided
researchers with three participants in each of five age groups. The Cronbach’s alpha coefficient, a measure of internal reliability,
was 0.765 for the survey. Then, all statistically non-significant items were deleted. This resulted in an internally reliable 17
statement online survey that was emailed by the Insulet Corporation to potential participants as described below. Other testretest reliability estimates were not done because of the time constraint that limited a test-retest opportunity.
Procedures
The Investigative Review Board (IRB) provided approval. The researchers followed all procedures listed in the protocol. An
online informed consent form described study benefits and risks, voluntary participation, withdrawal at any time without penalty,
and clarified that all procedures followed IRB approved standards for non-disclosure of identity. Selecting the agreement icon,
signified an automated signature of informed consent by a participant.20 The study was approved for adults over 18 years.
Children and women with gestational diabetes were excluded.
An invitation from the Insulet Corporation was emailed to potential participants that provided a link directing volunteers to the
university web-host site to complete the survey. Only people receiving the email could take the validated survey. The survey took
approximately 5 to 7 minutes to complete. After completion, responders automatically received a thank you email from Insulet
Corporation. The survey results were accessible on the website for a period of 30 days. A follow-up invitation was sent again by
the Insulet Corporation at the two week midpoint to increase the survey’s response rate. The 30-day window limited the response
rate, as did the distribution during the period after Thanksgiving and before Christmas; however, this was a graduate student
project that required completion by graduation. Demographic questions helped to determine two tracks to separate FTUs from
STUs. FTUs had no experience with insulin pumps with tubes prior to purchasing a tubeless pump. STU participants had been
using insulin pumps with tubes for at least 5 years and had switched to the tubeless devices within the previous year.
Completed surveys were removed by the database manager after study completion. A unique identifier was assigned to each
participant to ensure that only one response was received.20 To insure confidentiality, the corporation never had access to the
survey database and the university never had access to participant names and emails.20 Only participants who rated every
statement were included in the study.
RESULTS
Statistical Analysis
The descriptive statistics of all variables were presented as means and standard deviations in frequency tables and graphs.
Answers to the statements, grouped as Agree/Disagree, were the binary response variables of main interest. The logistic
regression analysis was used to evaluate the effect of Group (FTUs versus STUs) on each of the binary variables, while
controlling for age (18 to 25 years, 26 to 35 years, 36 to 50 years, 51 to 70 years, and 70+ years) and gender (female versus
male) categories in the model. SAS® software version 9.2 was used to perform all statistical analyses. All tests were conducted
at the 0.05 level of significance. Percentages did not total 100. The neutral position (number 3) on the Likert scale was excluded
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from calculations because none of the participants chose this answer. Wald Chi Square calculations were used to test the true
value of the association.21 P-values and odds ratio estimates were reported.21 An odds ratio estimate of one showed equal odds
of occurrence for each group under consideration.21
Demographics
There were 959 complete responses to the survey or approximately 10% of the distribution. This was a low response rate, as
24% to 76% response would be more typical.20 The nationwide convenience sample was comprised of people from 39/52 states.
The researchers were unable to send repeated reminders to increase the response rate because of semester and funding time
limitations. In addition, the majority (95%) of participants in the study were Caucasian, with American-Indians, African-Americans,
Latino-Americans constituting just 5% of the sample. Table 1 depicted the age, gender, ethnicity, type of diabetes, and duration
of diabetes. The majority of users (99.75%) had insurance reimbursement for durable medical equipment and coverable supplies
by prescription.

Characteristics by Groups
Age
18 to 25
26 to 35
36 to 50
51 to 70
71+
Gender
Male
Female
Ethnicity
American Indian
Alaska Native
Asian
African-American
Latino-American

Table 1. Demographic Characteristics by Groups
First Time Pump Users
FTUs ( n = 534)
n
%
74
13.86
120
22.47
174
32.58
159
29.78
7
1.31

Second Time Pump Users
STUs (n = 425)
n
%
53
12.47
102
24.00
140
32.94
127
29.99
3
00.71

243
291

45.51
54.49

161
264

37.88
62.12

0
2
1
11
16

0.00
0.37
0.19
2.06
3.00

0
1
0
7
11

0.00
0.24
00.00
1.65
2.59

Native Hawaiian or other Pacific
Islander

0

0.00

0

0.00

White
Ethnicity withheld

493
11

92.32
2.06

400
6

94.12
1.41

Data Analysis
The two groups were comprised of FTUs (n= 534) and STUs (n= 425). Additionally, most of the respondents had Type I diabetes
mellitus (84% FTUs, 92.71% STUs) n = 853 (88% of the sample). The largest group representations were by 36 to 50 year olds
(32.58% FTUs, 32.94% STUs), females (54.49% FTUs, 62.12% STUs), and non-Hispanic whites (92.32% FTUs, 94.12% STUs).
Participants with diabetes for 10 to 25 years represented 35.02% FTUs and 36.94% STUs.
There were gender effects that have been listed in Table 2 below showing the frequency of agreement/disagreement, p values
and odds ratio estimates. Of the survey results reported by statements shown in Table 2, four were statistically significant
(p<0.05), three were very significant (p< 0.01), and ten were highly significant (p<0.0001) for Group effect with women. Findings
for men revealed that three statements were significant, four were very significant and one was highly significant for men and
very significant for women and eight had no significance. Odds ratio estimates predicted that adult females as a group were 4.5
times more likely to worry about how they would wear their clothing than males, followed by 26 to 35 year olds that were the 2.9
times more likely than 51+ year olds to be concerned. These predictions suggested that females may be more vulnerable and at
risk for discontinuance of CSII. Knowledge of this result may alert clinicians to support females to better manage their self-care
through active practice in developing problem-solving abilities and coping strategies.
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Table 2. Group Effect: Significant Statements Comprising the Adaptation to Insulin Pumps Survey for Statistical
Comparisons of First Time Pump Users (FTU) and Second Time Pump Users (STU)
FTU % (n=534)

STU % (n=425)

Survey Statements
Agree/Disagree

Agree/Disagree

B= I thought my pump would prevent me from doing
daily activities.

32.002/ 55.43

22.83/ 66.59

B= I was concerned how I was going to wear my
clothing.

55.99/32.21

72.00/22.82

B= I was afraid I wouldn’t be able to operate my pump.

23.59/66.48

18.35/73.88

B= I was concerned that the pump would not be secure
on my body.

61.99/27.90

56.47/33.18

B= I thought that I would gain weight.

22.47/52.99

24.94/52.94

B= I was concerned about the cost of supplies.

67.23/20.79

66.35/23.53

B= I didn’t receive enough information about operating
the pump.

10.11/81.65

8.71/84.47

A= I feel better with more stable blood glucose wearing
my pump.

82.02/6.18

89.88/3.53

A= I’m open to the benefits of using a pump.

93.63/3.00

96.47/0.47

AD= The pump improved my quality of life.

91.20/3.38

93.64/1.18

AD= I’m able to do more fun and enjoyable activities.

38.77/15.55

52.23/9.65

AD= I enjoy a wider variety of foods.

55.24/15.73

71.53/8.71

I= Pump interferes with leisure or social activities with
family and friends.

13.85/ 74.53

35.29/49.41

I= Pump interferes with physical activities.

24.53/64.61

50.59/39.29

I= Pump interferes with religious practices.

1.31/74.91

4.70/67.05

I= Pump interferes with my community activities.

6.18/77.72

18.12/59.53

I= Pump interferes with the way I look.

27.15/59.18

35.30/45.88

Note: Statement key: B=Barriers, A=Attitude, AD= Adaptations, and I=Intrusiveness
There were no differences between the groups in adaptation statements.
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Odds Ratio
[95% CI]
p-value Female

Odds Ratio
[95% CI]
p-value Male

1.73
[1.27, 2.34]
p<0.0004
0.55
[0.40, 0.76]
p<0.0001
1.58
[1.13, 2.21]
p<0.0071
4.95
[3.64, 6.73]
p<0.0001
0.15
[0.11, 0.21]
p<0.0001
33.05
[22.02, 49.62]
p<0.0001
0.66
[0.44,0.97]
p<0.0356
0.51
[0.27, 0.96]
p<0.0379
0.15
[0.03, 0.64]
p<0.0105
0.32
[0.12, 0.89]
p<0.0280
0.46
[0.30, 0.70]
p<0.0003
0.43
[0.28, 0.66]
p<0.0001
0.26
[0.19, 0.36]
p<0.0001
0.28
[0.21, 0.38]
p<0.0001
0.26
[0.11, 0.64]
p<0.0031
0.26
[0.17, 0.40]
p<0.0001
2.84
(2.06, 3.92)
p <0.0001

0.98
[0.72, 1.33]
p<0.8882
4.49
[3.28, 6.15]
p<0.0002
3.41
[2.37, 4.92]
p <0.0001
1.47
[1.08, 1.99]
p<0.0141
1.87
[1.35, 2.59]
p< 0.0002
1.15
[0.79, 1.66]
p<0.4680
1.04
[0.69, 1.55]
p<0.8600
0.91
[0.50, 1.65]
p<0.7554
0.32
[0.10, 0.99]
p<0.0473
0.64
[0.27, 1.55]
p<0.3258
1.15
[0.76, 1.74]
p<0.5058
1.03
[0.69, 1.54]
p<0.8966
1.16
[0.83, 1.62]
p<0.3852
0.91
[0.68, 1.22]
p<0.5348
2.62
[0.97, 7.10]
p<0.0583
1.12
[0.73, 1.73]
p< 0.6097
0.63
(0.47, 0.86)
p<0.0032
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DISCUSSION OF FINDINGS
This study appeared to provide the first survey for insulin pump users in the literature that compared barriers, intrusiveness,
attitudes, and adaptations between inexperienced and experienced users of CSII biomedical devices.
The American Diabetes Association set standards that recognized the need for psychosocial screenings to assess an individual’s
attitude towards diabetes, emotional well-being, overall management, quality of life, and psychiatric comorbidities. Any gross
non-adherence, cognitive impairments, depression or other dangers to the client warranted referrals to experts for treatment.22
Likewise, the American Association of Diabetes Educators (AADE) suggested health educators should refer people with
adjustment issues to psychologists and social workers for support.23
The odds ratio estimates suggested that women may be more vulnerable to discontinuation of insulin pumps than males that had
been reported in children and adolescents. Psychosocial factors of adjustment using CSII were recognized as important
considerations in the child/adolescent population, but less has been written about other psychosocial adjustments to CSII
devices in other age groups.24,25 Most importantly, it was reported that low confidence in one’s ability to succeed with CSII
therapy portends failure.26
SIMILAR FINDINGS
Adapting to wearable biomedical device technology may pose many challenges, but information about people who made poor
adjustment to the technology was limited. Only two studies were identified that reported discontinuance of CSII devices, where
the participants chose to return to MDI. In a pediatric retrospective study of 530 CSII users with T1DM during 2000 to 2008,
researchers reported 11.3% of users discontinued pump use between three days and five years, and 9.1% discontinued in 3
months.27 Additionally, females >10 years old had the highest frequency of discontinuation representing 46% of the 75 females in
the study (p < 0.001), with 80% of participants being greater than 10 years old when they discontinued CSII. Other researchers
conducted a meta-analysis of 52 studies on (1,547 participants) comprised of adults, adolescents and children using CSII, in
order to study the impact of the therapy on metabolic and psychosocial outcomes.28 These researchers discovered five
retrospective studies about discontinuation of pump therapy that were obtained during clinic visits and by follow-up
questionnaires. The studies indicated 32% of 400 adult participants discontinued CSII devices because of: the discomfort of
wearing pumps, lack of improved glycemic control, and the frequency of diabetic ketoacidosis, pump malfunction, hypoglycemia,
site infections, or catheter occlusions. Discontinuance in this meta-analysis was correlated with psychiatric problems, females,
younger age, single or divorced status, and shorter duration of diabetes.28
Only one qualitative study was found regarding the psychosocial adjustment to CSII devices.29 The researchers identified themes
about the shared lived experiences and cultural perspectives of six Mexican-American adults, who had transitioned from insulin
injections to CSII. Although the duration of time that participants used CSII devices ranged from 6 months to 7.5 years, all
participants experienced the frustration of re-learning how to manage diabetes differently than when they used MDI. Males
agreed that their adaptation to the technology seemed easier for them than for females in the group. Everyone agreed that their
expectations for the CSII device were unrealistic at first, thinking that a pump was magically going to make their lives easier.
They also perceived that wearing a pump publically demonstrated that they had diabetes and revealed a personal weakness to
others. Women perceived that their weakness was less apparent with MDI than when using CSII. Both genders had perceived
that the pump interfered with intimacy. Women had more challenges in finding strategies to adapt their various types of clothing
to hide their pumps. For all participants, the adaptation process challenged them to redefine their self-perceptions.29 Findings of
this qualitative study were similar to those revealed by the Adaptation to Insulin Pumps Survey, which suggested that women
might need additional assistance during the adjustment process to the technology, in order to help them improve their problemsolving abilities and coping skills regarding issues of self-care.
This study adds to the literature by suggesting that adult females may have greater risk for discontinuance of the state of the art
biomedical technology for people with diabetes. Those women who show signs of discontent may quit without intervention.
Findings of this research may provide doctors, physician’s assistants, nurse practitioners, nurses, health educators, clinical
service managers, biomedical engineers designing such devices, and occupational therapists, insight as to why some adults do
well with the adjustment process to a CSII device and some return to MDI. All members of the treatment team should be involved
in secondary prevention in diabetes care, which in this case would be prevention of discontinuance of this life-extending
technology by poorly adapted users.
Implications
Occupational therapists may be missing team members. Meta-analyses have indicated that female adults, adolescents and
children using CSII devices may be at risk for discontinuation. Occupational therapists have expertise in helping people manage
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self-care and can help people adapt to daily living challenges in all health care settings, schools and after school programs. Their
education enables them to provide activities to facilitate psychosocial adjustment and to learn to adapt to new situations. They
are also accustomed to working assistive technologies. Occupational therapists work by prescription from physicians, physician’s
assistants, and nurse practitioners. Their treatment plans engage clients in occupation-based activities that involve practice of
the everyday activities of people with diabetes who use CSII devices, in order to help their clients expand their problem-solving
and coping skills. Occupational therapy interventions may be reimbursed in state insurance codes under billing for self-care. To
promulgate referrals to occupational therapists, health care practitioners will need to learn more about the day-to-day challenges
of living with diabetes, and particularly the specifics of CSII management in people from various cultures.30 Recently,
occupational therapists have provided evidence-based practice in secondary prevention of the tertiary complications of diabetes,
but there was only one study on CSII devices.31-35
Limitations
Results of this study needed cautious interpretation, as only 10% of potential respondents participated in the study. There were
several limitations. People who discontinued CSII devices were not recruited in this study. The majority of respondents were nonHispanic white-Americans. Minorities with health disparities were not well-represented in the sample, perhaps because they
lacked health insurance (to defray some of the expenses associated with CSII devices) and/or Internet access. Younger
participants, who use computers more than adults over age 70, dominated this sample survey. There was an expected difference
between groups because STUs were already familiar with the technology, whereas FTUs had no experience using the
biomedical device; however, the details of those differences were undiscovered. Lastly, thirteen states were not represented in
the sample.
FUTURE STUDIES
Future studies should investigate a larger multi-ethnic sample of CSII device users. The issues faced by those who are
contemplating purchasing a CSII device should be identified. Surveys could be given by paper and online to capture a broader
adult sample. Those practitioners who engage in this research should perform long-term studies to document retention rates and
reduction in complications that would enable third party providers to see the benefits of CSII devices in the future, in order to
reduce health disparities, the high cost of care, and sustain long-term usage of CSII devices.
CONCLUSIONS
This paper presented the results of a nationwide survey that was constructed to determine the issues that persons with diabetes
may experience when adjusting to CSII devices. The subjects were divided into two groups to determine whether experience
with CSII made a difference when learning to use CSII devices. Age was also a factor in successful adaptation. The validated
survey instrument reported 17 perceived barriers, intrusiveness issues, attitudes and adaptations of responders using CSII
devices. Ninety-four percent of calculated p values of statements were higher for woman than men. Odds ratio estimates
suggested that women may be more vulnerable and have greater risk for discontinuation of CSII devices, the amazing health
promoting biomedical technology that can lengthen lifespan and reduce complications. Future research should identify women at
risk and clarify the roles of different healthcare practitioners in addressing the self-care adjustment issues of women.
It will also be necessary to identify the evidence-based interventions that improve outcomes for women at risk, in order to expand
practice in this area of secondary prevention.
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